Medizinische Universität Graz - Research portal
Selected Publication:
Attarbaschi, A; Mann, G; Dworzak, M; Trebo, M; Urban, C; Fink, FM; Horcher, E; Reiter, A; Riehm, H; Gadner, H; Austrian Cooperative Study Group.
Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
Wien Klin Wochenschr. 2002; 114(23-24):978-986
Web of Science
PubMed
Google Scholar
- Co-authors Med Uni Graz
- Urban Ernst-Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- Between 1986 and 2000 183 Austrian children and adolescents with non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-ALL) were enrolled in 3 consecutive studies of the Berlin-Frankfurt-Münster (BFM) Group. In trial NHL-BFM 86, patients were stratified according to the histologic subtype and clinical stage. In the succeeding studies NHL-BFM 90 and 95, treatment stratification was additionally based on the speed of tumor response to therapy and for children with B-cell NHL/B-ALL also on the pre-therapeutic serum lactic dehydrogenase level. Event-free survival rates were 84% +/- 6% in trial NHL-BFM 86 (n = 39) and 86% +/- 4% in both trials NHL-BFM 90 (n = 67) and NHL-BFM 95 (n = 77). Patients with lymphoblastic lymphoma (mainly with T-cell phenotypes) had an excellent prognosis with an ALL-type chemotherapy regimen (n = 49; relapse, n = 1), whereas an intensive, short-pulse therapy delivered within a 2- to 4-month period was found to be highly efficacious in children with B-cell NHL/B-ALL (n = 114; relapse, n = 6; progression, n = 5). Patients with anaplastic large cell lymphoma (ALCL) who were treated with similar alternating short courses of multi-agent chemotherapy had a less good outcome (n = 20; relapse, n = 6, progression, n = 3). Children with B-cell NHL and B-ALL who failed initial therapy also had a dismal prognosis (10/11 patients died). Local radiotherapy as a part of lymphoma therapy was completely abandoned in study NHL-BFM 90 and surgical interventions were confined to specific situations such as complete resection in localized B-cell NHL and ALCL, diagnostic biopsy and second-look operation. In conclusion, our results showed that the BFM treatment strategy for lymphoblastic lymphoma and B-cell NHL/B-ALL was highly successful in the majority of patients; however, optimal treatment for children with ALCL has not yet been defined. As a consequence, larger trials at an international level are necessary to find new prognostic markers that might define more precisely those patients who need further intensification of first-line treatment or novel therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Antineoplastic Agents - administration and dosage
- Child - administration and dosage
- Child, Preschool - administration and dosage
- Data Interpretation, Statistical - administration and dosage
- Disease-Free Survival - administration and dosage
- Female - administration and dosage
- Follow-Up Studies - administration and dosage
- Humans - administration and dosage
- Infant - administration and dosage
- Leukemia, B-Cell, Acute - diagnosis
- Lymphoma, B-Cell - diagnosis
- Lymphoma, Lymphoblastic - diagnosis
- Lymphoma, Non-Hodgkin - diagnosis
- Male - diagnosis
- Prognosis - diagnosis
- Prospective Studies - diagnosis
- Risk Factors - diagnosis
- Survival Analysis - diagnosis
- Time Factors - diagnosis
- Treatment Outcome - diagnosis
- Find related publications in this database (Keywords)
- non-Hodgkin's lymphoma (NHL)
- mature B-cell acute leukemia (B-ALL)
- treatment stratification
- treatment protocols
- prognosis